Payment overview · 2025
General Payments
$95.82
5 reported records · 5 companies
Healthcare provider profile · identity verified
Daniel Berens, DO
Allopathic & Osteopathic Physicians|Family Medicine · SPEARFISH, SD · NPI 1316201304
Verified facts
What the public records show
CMS Open Payments records show Daniel Berens, DO received $95.82 in general payments during 2025 across 5 reported records.
Globus Medical, Inc. accounted for 30.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $29.18 | 30.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.17 | 21.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.92 | 18.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.41 | 15.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.14 | 14.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $95.82 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $29.18 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.17 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.41 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.41 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 82 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 137 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
82 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
137 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
134 | 40 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 673 | 195 |
| Levothyroxine Sodium | Levothyroxine Sodium | 504 | 117 |
| Losartan Potassium | Losartan Potassium | 493 | 140 |
| Lisinopril | Lisinopril | 404 | 117 |
| Amlodipine Besylate | Amlodipine Besylate | 377 | 95 |
| Metoprolol Succinate | Metoprolol Succinate | 330 | 90 |
| Omeprazole | Omeprazole | 322 | 90 |
| Hydrochlorothiazide | Hydrochlorothiazide | 256 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 227 | 70 |
| Potassium Chloride | Potassium Chloride | 218 | 68 |
| Furosemide | Furosemide | 199 | 56 |
| Gabapentin | Gabapentin | 194 | 61 |
| Metformin Hcl | Metformin Hcl | 190 | 55 |
| Simvastatin | Simvastatin | 178 | 52 |
| Trazodone Hcl | Trazodone Hcl | 178 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 148 | 52 |
| Ozempic | Semaglutide | 137 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 135 | 29 |
| Eliquis | Apixaban | 134 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 133 | 39 |
| Allopurinol | Allopurinol | 122 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 117 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 115 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 111 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 107 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 103 | 27 |
| Metformin Hcl Er | Metformin Hcl | 102 | 25 |
| Tramadol Hcl | Tramadol Hcl | 97 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 95 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 94 | 23 |
| Trulicity | Dulaglutide | 89 | 13 |
| Jardiance | Empagliflozin | 82 | 24 |
| Warfarin Sodium | Warfarin Sodium | 79 | 15 |
| Clonazepam | Clonazepam | 78 | 13 |
| Montelukast Sodium | Montelukast Sodium | 77 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 73 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 72 | 24 |
| Alendronate Sodium | Alendronate Sodium | 71 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 71 | 14 |
| Finasteride | Finasteride | 71 | 20 |
| Meloxicam | Meloxicam | 71 | 25 |
| Bupropion Xl | Bupropion Hcl | 68 | 13 |
| Carvedilol | Carvedilol | 66 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 66 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 65 | 22 |
| Spironolactone | Spironolactone | 65 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 64 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 54 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | suppressed |
| Lansoprazole | Lansoprazole | 51 | 13 |
| Synthroid | Levothyroxine Sodium | 50 | 13 |
| Pregabalin | Pregabalin | 49 | 13 |
| Ezetimibe | Ezetimibe | 47 | 15 |
| Famotidine | Famotidine | 47 | 16 |
| Tresiba Flextouch U-100 | Insulin Degludec | 46 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 45 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 24 |
| Celecoxib | Celecoxib | 43 | 16 |
| Prednisone | Prednisone | 43 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 43 | 13 |
| Mounjaro | Tirzepatide | 40 | suppressed |
| Atenolol | Atenolol | 39 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 38 | 25 |
| Bumetanide | Bumetanide | 38 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | 11 |
| Primidone | Primidone | 35 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 33 | suppressed |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 31 | suppressed |
| Valsartan | Valsartan | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Latanoprost | Latanoprost | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 17 |
| Cephalexin | Cephalexin | 21 | 15 |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Trospium Chloride Er | Trospium Chloride | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 17 |
| Dutasteride | Dutasteride | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Alprazolam | Alprazolam | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 11 | 11 |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $95.82 · 5 records | Globus Medical, Inc. | ABRYSVO, COMIRNATY, JARDIANCE, Ozempic, PREVNAR 20, Rybelsus, Senza, The Cologuard Plus Collection Kit | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error